摘要 : Summary Neurodegeneration in Langerhans cell histiocytosis (ND‐LCH) is a major clinical issue requiring urgent resolution. Sveijer et al. showed that plasma neurofilament light protein is a promising biomarker for screening patie... 展开 Summary Neurodegeneration in Langerhans cell histiocytosis (ND‐LCH) is a major clinical issue requiring urgent resolution. Sveijer et al. showed that plasma neurofilament light protein is a promising biomarker for screening patients with ND‐LCH and determining the therapeutic effect of a mitogen‐activated protein kinase inhibitor. Therefore, this can be a powerful tool for conducting clinical trials for ND‐LCH. Commentary on: Sveijer M, von Bahr Greenwood T, J?dersten M, Kvedaraite E, Zetterberg H, Blennow K, et al. Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma. Br J Haematol. 2022;198:722–729 收起